Phase 2 Prostate Cancer Trial, Recruiting NCT06449781 Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT06449781
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have signed a written consent form agreeing to take part in the study
  • People who have been diagnosed with high or very high risk prostate cancer, confirmed by a laboratory examination of tissue
  • People who have completed radical local treatment for their prostate cancer
  • People whose local treatment was completed within 3 months before joining the study
  • People who are generally well enough to carry out daily activities, rated on a standard scale from 0 (fully active) to 2 (up and about more than half the day) (confirm with trial site)
  • People aged 18 years or older
  • People who had no signs of cancer spread shown on imaging scans within 28 days before entering the study
  • People whose testosterone levels are at a very low "castrate" level (below 50 ng/dL or 1.7 nmol/L)
  • People whose bone marrow, liver, and kidneys are functioning well enough to meet specific blood and laboratory test thresholds (confirm with trial site for exact values)
  • Men of reproductive age who are willing to use two forms of contraception at the same time during the trial

Who may not be able to join:

  • People whose imaging scans confirm that cancer has spread to distant parts of the body
  • People who are not willing or able to use an effective method of contraception
  • People who do not consent to taking part in the study
  • People who have a blockage in their urinary tract or fluid build-up in the kidneys (hydronephrosis)
  • People who are currently receiving any other cancer treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 48322789339

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Registry
ClinicalTrials.gov
Start date
9 January 2025
Est. completion
1 November 2030

Where this trial is recruiting

🇵🇱 Poland

Primary endpoints

Treatment effectiveness

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov